Compare · ABT vs IFRX
ABT vs IFRX
Side-by-side comparison of Abbott Laboratories (ABT) and InflaRx N.V. (IFRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and IFRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $187.95B, about 1090.1x IFRX ($172.4M).
- ABT has been more active in the news (8 items in the past 4 weeks vs 6 for IFRX).
- ABT has more recent analyst coverage (25 ratings vs 13 for IFRX).
- Company
- Abbott Laboratories
- InflaRx N.V.
- Price
- -
- -
- Market cap
- $187.95B
- $172.4M
- 1M return
- +3.63%
- -
- 1Y return
- -16.55%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 8
- 6
- Recent ratings
- 25
- 13
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
InflaRx N.V.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Latest ABT
- New Abbott Panbio™ COVID-19/Flu A&B Self-Test Helps Canadian Families Make Informed Decisions During Respiratory Illness Season
- EXECUTIVE VICE PRESIDENT Moreland Mary K sold $406,000 worth of Common shares without par value (3,500 units at $116.00), decreasing direct ownership by 3% to 100,791 units (SEC Form 4)
- SEC Form 10-Q filed by Abbott Laboratories
- Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
- Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
- Abbott Labs downgraded by Argus
- Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
- Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
- Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm
Latest IFRX
- SEC Form 6-K filed by InflaRx N.V.
- InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan
- SEC Form 6-K filed by InflaRx N.V.
- SEC Form 6-K filed by InflaRx N.V.
- InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day
- InflaRx Announces November Investor Events
- SEC Form 6-K filed by InflaRx N.V.
- InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
- InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
- InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development